Tumour-infiltrating lymphocytes/central memory T cells therapy (Shanghai Biomed-union Biotechnology)

N/A

Report date: 2025/05/29 20:00:08

Base Information

Drug NameTumour-infiltrating lymphocytes/central memory T cells therapy (Shanghai Biomed-union Biotechnology)
Drug Alias NameAdoptive TIL-TCM transfer therapy
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsPancreatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaPending
Originator CompaniesShanghai Biomed-Union Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesShanghai Biomed-Union Biotechnology Co Ltd
Active IndicationsN/A
Inactive IndicationsPancreatic Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A